

ASX ANNOUNCEMENT

\$3.63 MILLION CAPITAL RAISING COMPLETED

- Completed \$3.63M capital raising via private placement
- 113.2M shares will be issued at 2.5 cents for a total of \$2.83M
- 26.6M shares will be issued at 3 cents for a total of \$800K
 - Expressions of interest for additional \$1M received
- CEO's contract extended for another three years to facilitate delivery on milestones

Sydney, 26 November 2009: Cellmid Limited (formerly Medical Therapies Limited) has today completed a private placement to sophisticated and professional investors raising \$3.63 million. The shares will be issued in two tranches due to the strong interest and substantial oversubscription in the private placement.

The first tranche of 113,200,000 shares will be issued immediately at 2.5 cents per share, raising \$2.83 million. This price represents a 13% discount to the average share price over the previous five trading days. The shares will be issued pursuant to the shareholders' approval received at the Company's Annual General Meeting on 17 November 2009.

The second tranche, a further 26,666,666 shares at 3 cents per share, raising \$800,000, will be issued on or before 1 March 2010. These shares will be issued within the 15% limit under Listing Rule 7.1.

In addition to the current \$3.63 million raising the company has also received expressions of interest from existing shareholders for another \$1 million funding to be provided on or before 30 June 2010. The terms of the additional investment are expected to be finalised by 1 March 2010.

"The two tranche structure allows for optimum access to working capital whilst limiting dilution" said Dr David King, Chairman of Cellmid. "We are encouraged by, and thankful for, the strong support from private and institutional shareholders, providing a platform for the Company to leverage its extensive IP portfolio around midkine" he added.

"We have received the first payment from our recent diagnostic license with Celera Corporation" said Maria Halasz. "Together with the funds just raised we are on solid ground to complete our therapeutic antibody validation programmes and further develop and commercialize our cancer diagnostic portfolio" she added.

In addition to completing the capital raising Maria Halasz, the CEO of Cellmid, has agreed to renew her employment agreement with the Company for an additional three years. In her new employment agreement all cash bonuses have been replaced by performance option incentives; all other terms of the prior contract remain the same.

“Maria has been the key driver of Cellmid’s transformation over the past two years. Her knowledge of the Company’s extensive IP portfolio and continued commitment are essential for keeping the momentum in our product development programmes, which we are confident will lead to increased shareholder returns” commented Dr King.

end

For further information visit www.cellmid.com.au or contact:

Dr David King, Chairman

T +612 92990311

About Cellmid Limited (ASX: CDY)

Cellmid Limited is a biotechnology company listed on the Australian Stock Exchange. The Company is the owner of the most comprehensive intellectual property portfolio around midkine globally. Midkine is a significant novel therapeutic and diagnostic target. It is a native protein expressed during early cancer formation as well as at the onset of a number of inflammatory processes. Cellmid is committed to the commercialisation of its portfolio of therapeutic and diagnostic products. In addition to its product development programs Cellmid is actively seeking partners for some of its non-core assets.

Investment in biotechnology companies

There are a number of inherent risks associated with the research, development and commercialisation of pharmaceutical products. Investment in companies specialising in these activities carry specific risks which are different to those associated with trading and manufacturing businesses. As such, these companies should be regarded as highly speculative. Medical Therapies recommends that investors seek professional advice before making an investment in its shares.